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* Impact Points of 2013 as stated on official website of the Journals 
Predictors of ICD Therapies  Arash Arya 
- 4 - 
 
Introduction (Einführung): 
There is no controversy that implantable cardioverter-defibrillator (ICD) in 
selected patients reduces the long term mortality. [1] However, in patients with ICD 
appropriate and/or inappropriate shocks are associated with increased mortality and 
morbidity. A recent meta-analysis showed a significant association between appropriate 
and inappropriate ICD shocks and mortality, with a stronger association for appropriate 
shocks. [1] In a recent study a total of 1398 consecutive patients of the ICD-registry 
Ludwigshafen who had an ICD implanted between 1992 and 2008 for primary or 
secondary prevention of sudden cardiac death were studied. [2] During the median 
follow-up time of 6 years, 749 (54%) patients experienced 17827 episodes of 
ventricular tachycardia (VT) or fibrillation (VF) which were terminated by anti-
tachycardia pacing (ATP) in 74% and by shock in 26% of patients. [2] 
In 321 of those patients with VT/VF, the first episode was terminated by ATP. 
[2] In a multivariable analysis, the occurrence of first ATP therapy was associated with 
a higher mortality rate [hazard ratio (HR) 2.60, 95% confidence interval (CI) 2.02-3.35]. 
When excluding all patients with appropriate ICD shocks first ATP therapy still 
associated with a worse prognosis (HR 1.92, 95% CI 1.38-2.67). [2] Therefore not only 
ICD shocks but also ATPs are associated with increased mortality.  
Identifying the predictors of ICD therapies could help to identify those at risk 
and reduce the incidence of these therapies which has detrimental effect on mortality 
and morbidity in patients with ICD. Identifying these patients is very important as 
prophylactic catheter ablation of VT can reduce the incidence of ICD therapies and 
therefore may improve the long term survival. [3] In SMASH-VT study 128 patients 
were randomly assigned to ICD implantation alone or with adjunctive prophylactic 
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catheter ablation. [3] Ablation was performed with the use of a substrate guided 
approach in which the myocardial scar is mapped and ablated while the heart remains 
predominantly in sinus rhythm. [3] During the follow up period of 22.5±5.5 months 
21(33%) and 7(12%) patients received appropriate ICD shocks in ICD alone and ICD 
plus adjunctive catheter ablation groups, respectively (hazard ratio in the ablation group, 
0.35; 95% confidence interval, 0.15 to 0.78, P = 0.007). [3]  
In addition early referral for catheter ablation of ventricular arrhythmias in these 
patients is associated with improved acute and long-term outcomes. [4] We studied 
recently 300 patients with sustained VT who underwent catheter ablation. [4] Catheter 
ablation was performed within 30 days after the first documented VT in 75 (25%) 
patients (group 1), between 1 month and 1 year in 84 (28%) patients (group 2), and >1 
year after the first VT occurrence in 141 (47%) patients (group 3). Recurrence-free 
survival was higher in group 1, as compared with group 2 (hazard ratio [HR], 1.85; 
P=0.009) and group 3 (HR, 2.04; P=0.001). VT recurrence (HR, 1.91; P=0.037) 
predicted cardiac mortality. These results showed that catheter ablation of scar-related 
VT performed within 30 days after the first documented VT was associated with 
improved acute and long-term outcome. [4] 
In the first manuscript (Part 1) we sought to find the prevalence and predictors of 
the electrical storm, defined as occurrence of ≥ 3 episodes of ventricular tachycardia 
and/or fibrillation in a one day period, in patients with ICD. Electrical storm severely 
impairs the quality of life and associated with increased mortality.  
One hundred sixty two patients with ICD were included in this study and were 
followed for a mean of 14.3±10 months. After ICD implantation the patients were 
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followed on a regular basis (3 months) and upon receiving high voltage therapy in our 
outpatient ICD clinic. The devices were interrogated at each session and the complete 
set of data (including intra-cardiac electrograms) was recorded.  
The algorithms that should discriminate VT or VF from less lethal supra-
ventricular arrhythmias do not always work perfectly. As many as one-third of the 
patients who have an ICD implanted, receive inappropriate ICD shocks. [1] 
Inappropriate shocks occur when the device delivers a high-voltage discharge for a 
reason other than a ventricular arrhythmia. As stated above not only appropriate but also 
inappropriate ICD shocks are associated with increased mortality. [1] Patients describe 
an ICD shock as “an earthquake,” or “being hit by a truck”. [1, 5] Given the traumatic 
nature of ICD shocks, it would be ideal if the ICD could always successfully distinguish 
ventricular arrhythmias from non–life-threatening tachyarrhythmias and administer only 
appropriate shocks for VT or VT. [6]  
Several studies have suggested that quality of life is influenced adversely in 
patients who experience appropriate and/or inappropriate ICD shocks. [1] For example, 
in the SCD-HeFT study patients who received shocks within one month of a scheduled 
assessment had substantially worse quality of life compared to those without ICD 
shocks. [7]  
Several factors influence the incidence and prevalence of inappropriate ICD 
shocks. Every ICD manufacturer uses a different discrimination protocol and therefore 
the rate of inappropriate ICD therapies might be different among various ICD models.  
However, at the time of our second study to the best of our knowledge no study 
assessed the rate of inappropriate ICD shocks between different ICD manufacturers.  
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This was a single centre study to analyze and compare the probability of ≥1 
inappropriate ICD therapies between the two manufacturers after trans-venous ICD 
implantation. To prevent disclosure of data on the two ICD manufacturers we named 
them as manufacturer “A” (n=113) and “B” (n=49) and did not mention the ICD models 
and detailed programming variables. Immediately after implantation the detection and 
discrimination criteria were activated with the nominal values. We used the nominal 
values after implantation for comparison of discriminatory protocols of the two 
manufacturers under default settings. During all initial programming in all the devices 
we defined ventricular fibrillation zone (300 ms) plus one ventricular tachycardia zone 
(400 ms). If the patient had an episode of spontaneous or induced sustained 
monomorphic ventricular tachycardia slower than 370 ms (5 patients, three received 
manufacturer A’s and 2 Manufacturer B’s ICDs) we extended the ventricular 
tachycardia zone to the arrhythmia cycle length plus 40 ms.  
After first inappropriate ICD therapy if deemed necessary, the attending 
physicians were able to modify ICD programming and optimize medical treatment in 
order to decrease the rate of inappropriate ICD therapy. Therefore, we just compared the 
occurrence of ≥ 1 appropriate ICD therapy between these two groups rather than total 
number of inappropriate ICD therapies. The results of this study are presented in Part 2 
of this dissertation.  
In the third part of this dissertation we assessed the role of first VT cycle length 
on subsequent incidence and prevalence of ventricular arrhythmias in patients with ICD. 
As stated in part 3 several studies assessed the effect of hemodynamic stability of the 
VTs on subsequent mortality and recurrence of VT.  
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Sarter et al. have suggested a better prognosis for hemodynamically tolerated 
VT but other showed that the risk is similar to patients with more severely symptomatic 
VT. Raitt et al. in a subgroup analysis of AVID registry showed that the absence of 
symptoms with sustained VT does not predict a benign prognosis. Olson et al. assessed 
the predictors of sudden cardiac death in 122 patients and showed that the rate of 
sudden cardiac death is not affected by presence or absence of symptoms during 
sustained monomorphic VT. [8, 9] 
Bocker and colleagues studied the natural course of 50 patients with 
hemodynamically tolerated VT who received ICD. They showed that during mean 
follow up of 17 months, 33 patients (66%)
 
had 3861 episodes of VTs. Eleven patients 
(22%) had
 
episodes of potentially life-threatening fast VT (CL<250 ms) during follow 
up period. Had the ICD not been implanted in the Bocker study, their patients would 
have had at least the same mortality as patients in AVID registry. [8, 10] 
The effect of first VT cycle length on the subsequent VT recurrence is largely 
unknown. We sough to assess the effect of cycle length of first VT episode (as the index 
arrhythmia) on total number of subsequent appropriate ICD therapies as a surrogate for 
total ventricular arrhythmia burden in a cohort of patients with ICD. We hypothesized 
that the first VT cycle lengths do not influence the total sustained ventricular arrhythmia 
burden, and therefore, the slow and fast VTs should be treated similar in these patients 
as our recent data have also shown. [4]  
One hundred ninety five patients (75% male) with structural heart disease who 
underwent ICD implantation were included in this study. Among these 45 patients with 
sustained monomorphic VT as the first arrhythmia requiring ICD therapy were included 
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in this study. The subgroups of arrhythmia cycle length are chosen based on the median 
values in the study population (Table 2, Part 3). During follow up 22% (n=5) and 19% 
(n=4) of the ICD recipients with initial fast and slow VT experiences at least one 
episode of potentially life threatening fast VT, defined as VT with cycle length ≤ 250 
ms, respectively (P = 0.853). [10] Further results and detailed analyses are presented in 
the third part of this dissertation. 
 In the final part of this dissertation we tried to answer the question if 
cardiac resynchronization therapy (CRT) affects the prevalence of ventricular 
arrhythmias. Cardiac resynchronization therapy is an established mode of therapy in 
selected symptomatic patients with heart failure due to systolic dysfunction. The 
published large scale clinical trials of CRT confirmed the favorable effects of CRT on 
symptoms, the quality of life, ventricular function, and blood pressure and showed that 
CRT significantly reduces the risk of mortality. Calculations based on data from 
Cardiac Resynchronization — Heart Failure trial depicted that, for every nine 
biventricular pacemaker implanted, one death and three hospitalizations for major 
cardiovascular events were prevented. The reduction in mortality by CRT is at least in 
some part is related to homodynamic improvement. [11-14]  
We conducted a retrospective case-control study to assess the effect of CRT on 
incidence of appropriate therapy, as a surrogate for sustained ventricular arrhythmias, in 
patients with ICD. Thirty one patients with biventricular ICD implantation were 
included in this study. All these patients had QRS width ≥ 120 ms and standard 
indication for CRT and ICD implantation. During the same period 68 patients with 
structural heart disease received dual chamber ICD. To provide an adequate comparable 
control group, among these 68 patients we selected all the patients with QRS duration ≥ 
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120 ms (n=34) as the control group. The detailed results of this study which showed that 
CRT decreased the rate of appropriate ICD therapy by suppressing the occurrence of 
sustained ventricular arrhythmias requiring ICD therapy are presented in part 4. During 
follow up period patients with biventricular ICD received 66% less appropriate ICD 
therapy compared to those with dual chamber ICD.  
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Dissertation zur Erlangung des akademischen Grades Dr. med. Teil 1 
Predictors of Electrical Storm and Appropriate Therapy in Patients 
with ICD and Structural Heart Disease 
eingereicht von: Arash Arya 
angefertigt am Herzzentrum Universität Leipzig 
Betreut von Prof. Dr. med. Gerhard Hindricks 
 
Abstract (Part 1)* 
Identifying predictors of electrical storm in patients with implantable cardioverter-defibrillator 
(ICD) could help to identify those at risk and reduce the incidence of this emergency situation which 
has detrimental effect on mortality and morbidity in patients with ICD. In this retrospective study we 
sought to find the prevalence and predictors of electrical storm in patients with ICD.  
One hundred sixty two patients (126 men, mean age 58±13 years) who received ICD between 
January 2001 and 2005 were included in the study. Clinical, electrocardiographic, and ICD stored data 
and electrograms were collected and analyzed. Twenty-two patients (14%) developed electrical storm 
during mean follow up of 14.3±10 months. Using Cox multiple regression analysis we found that 
ejection fraction < 25% (P=0.007), QRS width ≥ 120 ms (P=0.002), and lack of adjunctive angiotensin 
converting enzyme inhibitor and beta-blocker therapy (both P < 0.001) were correlated with higher 
probability of electrical storm. Adjunctive amiodarone and digoxin therapy, indication of ICD 
implantation, and age were not correlated with occurrence of electrical storm during the follow up (all 
P=NS).  
In conclusion, electrical storm is not uncommon among patients with ICD. Optimum medical 
therapy with beta-blockers and angiotensin converting enzyme inhibitors could reduce the occurrence 
of electrical storm and this especially should be persuaded among those who are at higher risk of this 
complication (i.e. those with left ventricular ejection fraction < 25% and QRS width ≥ 120 ms).  
 
* published in American Journal of Cardiology. 2006;97:389-92. Impact Factor (2013): 3.425 
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Introduction: 
Patients with an implantable cardioverter-defibrillator (ICD) can develop electrical 
storm, 
1-4 
defined as occurrence of ≥ 3 episodes of ventricular tachycardia and/or fibrillation in 
a one day period. 
3
 These patients frequently receive multiple ICD shocks, which severely 
impair quality of life. 
1-4 
Although both ventricular tachycardia and fibrillation could be 
responsible for electrical storm, ventricular tachycardia is the most common cause. Several 
studies have assessed the prevalence, and possible predictors of electrical storm in patients 
with ICD. 
1, 4-9
 In this study we assess the prevalence and predictors of electrical storm in a 
group of patients with ICD. 
Methods: 
Patients Population: Between January 2001 and January 2005, 196 patients with 
coronary artery disease or dilated cardiomyopathy underwent ICD implantation at our centre. 
We excluded patients with biventricular ICDs from our study (n=34). We included all the 
other patients (n=162) who received single or dual chamber ICD during the same period. All 
the patients gave written informed consent for the procedure of ICD implantation. 
Implanted ICDs: The implanted devices were manufactured by Medtronic ([GEM-
VR, GEM-DR, GEM-II-VR, GEM-II-DR, GEM-III-VR, GEM-III-DR, Marquis-VR, 
Marquis-DR] Medtronic Inc., Minneapolis, MN, USA, n=113) and St. Jude ([Photon-VR, 
Photon-DR, Photon-µ-VR, Photon-µ-DR, Atlas-VR, Atlas-DR, Epic-VR, and Epic-DR] St. 
Jude Medical Inc. Sylmar, CA, USA, n=49). Single and dual chamber ICDs were implanted 
in 107 and 55 patients, respectively. 
ICD Data Storage and Retrieval: After ICD implantation the patients were followed 
on a regular basis (3 months) and upon receiving high voltage therapy in our outpatient ICD 
clinic. The devices were interrogated at each session and the complete set of data (including 
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intra-cardiac electrograms) was recorded on floppy diskettes. The floppy diskettes were used 
to retrieve all sustained arrhythmia episodes resulted in ICD therapy. 
Definitions: Electrical storm was defined as ≥ 3 episodes of ventricular tachycardia 
and/or fibrillation requiring ICD therapy in a one day period. 
3
 Indication of ICD 
implantation was defined as secondary prevention (n=113) in patients who had experienced 
aborted sudden cardiac death, sustained ventricular arrhythmia, or syncope (whose 
electrophysiological study showed inducible sustained hemodynamically unstable ventricular 
arrhythmias). The indication of ICD implantation in all the other patients (23 patients with 
coronary artery disease without history of syncope who had left ventricular ejection fraction < 
40%, nonsustained ventricular tachycardia on Holter monitoring, and inducible sustained 
hemodynamically unstable ventricular arrhythmia during electrophysiologic study; and 26 
asymptomatic patients with dilated cardiomyopathy with nonsustained ventricular 
tachycardia during Holter monitoring who had inducible sustained hemodynamically unstable 




Statistics: Variables are expressed as mean ± SD, and percentage. Differences in 
frequency of characteristics were assessed by independent sample student’s t-test for 
continuous variables. Chi-square statistics (or fisher’s exact test if applicable) used for 
discrete variables. We used Cox regression analysis with forward selection method 
(likelihood ratio) to find the potential predictors of electrical storm after device implantation. 
Probability of electrical storm based on the time (month) to electrical storm after ICD 
implantation between different groups determined by the Kaplan-Meier analysis (with 
Mantel-Cox test) and the time to electrical storm plotted according to the Kaplan-Meier 
method. A two-tailed p-value < 0.05 was considered statistically significant. We used SPSS® 
13.0 (SPSS Inc. Chicago, IL, USA) for data storage and analysis.  
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Results: 
Baseline Characteristics: One hundred sixty two patients with ICD were followed 
for a mean of 14.3±10 months. We compared baseline patients’ characteristics between 
patients with (n=22) and without (n=140) electrical storm during follow up (Table 1). 




Yes (n=22) No (n=140) 
Age (year) 53±19 58±12 0.240 








































JT interval (ms) 353±58 350±46 0.809 






















β-blocker therapy 13 (60%) 109 (78%) 0.120 
Angiotensin converting enzyme inhibitor 17 (77%) 129 (92%) 0.044 
Digoxin 9 (41%) 60 (43%) 0.835 
Amiodarone 14 (64%) 97 (69%) 0.632 
 
* A two tailed P-value < 0.05 is considered significant. 
The subgroups of left ventricular ejection fraction and QRS duration are chosen based on the median 
value in study population. 
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Number of Appropriate ICD therapies: During our follow up period the patients 
received mean number of 17±29 (range 1 – 132) appropriate ICD therapy. Among these the 
number of appropriate ATP was 11.9±28 (range 0 – 131) and the number of appropriate shock 
therapy was 5.1±9.9 (range 1 – 56). The success rate of ATP therapy among the episodes in 
the VT detection zone was 88%. 
Predictors of electrical storm: Predictors of electrical storm were found by Cox 
regression. In the model ejection fraction < 25% (P=0.007), QRS width ≥ 120 ms (P=0.002), 
and lack of adjunctive beta-blocker and angiotensin-converting enzyme inhibitors (both P < 
0.001) were correlated with the higher probability of electrical storm during the follow up 
period. In our model underlying heart disease (0.391), age (P=0.348), indication of ICD 
implantation (P=0.296), and adjunctive amiodarone and digoxin therapy (P=0.238 and 
P=0.407, respectively) were not correlated with higher probability of electrical storm in our 
patients. Table 2 shows the odds ratios and 95% confidence interval for predictors of 
electrical storm in our patients. 
Table 2: Predictors of electrical storm 
Variables Odds ratio 95% confidence interval P value** 
QRS width ≥ 120 ms 5.87 2.0 – 16.8 0.001 
Ejection fraction < 25% 4.0 1.2 – 14.5 0.038 
Lack of beta-blocker therapy* 6.0 1.75 – 21.0 0.007 
Lack of ACE‡ inhibitor therapy* 6.12 1.47 – 25.5 0.017 
 
* These analyses were stratified for ejection fraction and QRS duration. The subgroups of left ventricular 
ejection fraction and QRS duration are chosen based on the median values in the study population. 
** The Mantel-Haentszel P-value is reported for these analyses. 
‡ Angiotensin converting enzyme inhibitor. 
 
Discussion 
This study showed that (1) electrical storm occurs in a significant minority of patients 
with ICD; (2) patients left ventricular ejection fraction < 25% and/or QRS duration ≥ 120 ms 
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are especially at greater risk of electrical storm (Figure 1); and (3) optimum medical therapy 
with beta-blockers and angiotensin-converting enzyme inhibitors could reduce the incidence 
of this devastating complication in patients with ICD. 
Studies have shown that up to 50%-70% of the patients received appropriate ICD 
therapy within the first two years of follow up. 
1, 11
 In addition 10 to 20% of ICD patients 
experience electrical storm during a follow up of three years. 
3
 In our study during mean 
follow up of 14.3±10 month 22 (13.6%) of patients had electrical storm. The difference in the 
rate of electrical storm in various studies probably reflects difference in patient population 
and follow up period.  
Six clinical trials have been published hitherto studying the possible effect of electrical 
storm on mortality in patients with ICD. 
1, 2, 4-6, 9
 Among these, four reports 
4-6, 9
 showed that 
electrical storm was an independent predictor of increased mortality. Therefore, development 
of electrical storm identifies patients with ICD who are at increased risk of mortality and this 
warrants closer medical follow up. 
6
 Currently we do not know whether electrical storm plays 
a contributing or bystander role in the observed excess mortality. 
6
 However, other studies 
have shown that the independent predictors of electrical storm in our study are independent 
predictors of mortality in comparable patients’ population. 12-16 
Clinical profile of patients with electrical storm: Gatzoulis et al. have recently 
shown that the underlying heart disease did not predict electrical storm in patients with ICD. 
4
 
Verma et al. demonstrated that coronary artery disease as the underlying heart disease was an 
independent predictor of electrical storm among 2028 patients with ICD. 
5
 The prevalence of 
electrical storm in our patients was equal in patients who received ICD for primary versus 
secondary prevention of sudden cardiac death (Table 1). However, Gatzoulis et al. stated that 
among their patients in whom the ICD was implanted for primary prevention of sudden 
cardiac death (n=18) none experienced electrical storm during the follow up period. 
4
 These 
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differences could be explained by different patients’ population and characteristics (see 
definition). Left ventricular ejection fraction < 25% and QRS width ≥ 120 ms were 
independent predictors of electrical storm in our ICD patients (Figure 1). Low ejection 
fraction and wide QRS complexes are well known predictors of mortality in similar patients’ 
population. 
12, 15
 These simple risk predictors could help to select ICD patients who are at 
increased risk of electrical storm and mortality. The concomitant medical therapy should be 
optimized in ICD patients (and especially in this high risk subgroup) to reduce the risk of 
electrical storm. The antiarrhythmic effects of beta-blocker and angiotensin converting 
enzyme inhibitor and their favourable effect on mortality now are well known. 
3, 13, 14, 16
 
Therefore, especial attention should be paid to adjunctive medical therapy in ICD patients as 
this could decrease the risk of electrical storm and mortality (in addition to effect of ICD). 





Kaplan–Meier plot of the time to the first electrical storm according to subgroups of left ventricular 
ejection fraction (A) and QRS duration (B). The subgroups of left ventricular ejection fraction and 
QRS duration are chosen based on the median values in the study population. We used Log-Rank 
(Mantel-Cox) test to generate the P-value. 
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Dissertation zur Erlangung des akademischen Grades Dr. med. Teil 2 
Does the Rate of Inappropriate Therapy Differ in Implantable 
Cardioverter-Defibrillators from Different Manufacturers? 
eingereicht von: Arash Arya 
angefertigt am Herzzentrum Universität Leipzig 
Betreut von Prof. Dr. med. Gerhard Hindricks 
Abstract (Part 2)* 
This study was conducted to compare the rate of ≥1 inappropriate therapy between 
ICDs from two manufacturers which use different discriminatory protocols.  
One hundred sixty two patients (mean age 58±13 years, 126 male) who received ICDs 
between January 2001 and 2005 were included in the study. Clinical, electrocardiographic, 
and ICD stored data and electrograms were collected and analyzed. Immediately after 
implantation all the detection and discrimination criteria were activated with the nominal 
values in order to compare the two discriminatory protocols under the default manufacturer’s 
settings. During the follow up period of 14.3±10 months, 49 (30%) patients received ≥1 
inappropriate ICD therapy. The rate of ≥1 inappropriate ICD therapy in manufacturer A and B 
ICDs was 26% (n=29) and 41% (n=20), respectively. Comparing the rate of ≥1 inappropriate 
ICD therapy between the two groups by Kaplan-Meier analysis and the log rank test resulted 
in P =0.04.  
Having all discriminatory variables activated with the nominal values, discriminatory 
performance differs between the two manufacturers. Further larger-scale studies are warranted 
to prospectively compare the performance of various available ICDs’ discriminatory 
protocols, and define the optimum combination of discriminators in each ICD to decrease the 
rate of inappropriate therapy. 
 
* published in Journal of Interventional Electrophysiology. 2006;15:65-8. Impact Factor (2013): 1.552
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Introduction: 
A major issue in patients with implantable cardioverter-defibrillator (ICD) is 
inappropriate therapies, which have a major impact on morbidity and quality of life.
1-2
 To the 
best of our knowledge no study has assessed the rate of inappropriate therapy between ICDs 
from different manufacturers which use different discriminatory protocols. This is a single 
centre study to analyze and compare the probability of ≥1 inappropriate ICD therapies 
between the two manufacturers after trans-venous ICD implantation. 
Methods 
Patient population: (see section one, above for the patients’ population) Table 1 
shows the baseline characteristics of the patients. 
Implanted ICDs and programming: To prevent disclosure of data on the two ICD 
manufacturers we named them as manufacturer “A” (n=113) and “B” (n=49) and did not 
mention the ICD models and detailed programming variables. The devices from these 
manufacturers comprise 95% of the ICDs which are implanted at our centre. Immediately 
after implantation all the detection and discrimination criteria were activated with the nominal 
values. We used the nominal values after implantation for comparison of discriminatory 
protocols of the two manufacturers under default settings. During all initial programming in 
all the devices we defined ventricular fibrillation zone (300 ms) plus one ventricular 
tachycardia zone (400 ms). If the patient had an episode of spontaneous or induced sustained 
monomorphic ventricular tachycardia slower than 370 ms (5 patients, three received 
manufacturer A’s and 2 Manufacturer B’s ICDs) we extended the ventricular tachycardia 
zone to the arrhythmia cycle length plus 40 ms. After first inappropriate ICD therapy if 
deemed necessary, the attending physicians were able to modify ICD programming and 
optimize medical treatment in order to decrease the rate of inappropriate ICD therapy. 
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Therefore, we just compared the occurrence of ≥ 1 appropriate ICD therapy between these 
two groups rather than total number of inappropriate ICD therapies. 
Table 1: Baseline characteristics of patients 
Variables Manufacturer A Manufacturer B P-Value 
Number 113 (66%) 49 (34%) -- 
Rate of ≥ 1 inappropriate ICD therapy 29 (26%) 20 (41%) 0.045 * 
Reasons of 1
st
 inappropriate ICD therapy 
Sinus tachycardia 
Atrial tachycardia/fibrillation 

































Underlying heart disease:      










Left ventricular ejection fraction (%) 29±10 31±10 0.14 
QRS duration (ms) 108±30 108±36 0.93 
JT interval (ms) 351±52 351±37 0.91 
Type of ICD:        
Single chamber ICD 




















β-blocker therapy 80 (71%) 32 (65%) 0.57 
ACE ‡ Inhibitors 102 (90%) 44 (89%) 0.93 
Digoxin 51 (45%) 18 (37%) 0.27 
Amiodarone 80 (70%) 31 (63%) 0.25 
 
* Unadjusted P value by chi-square statistics 
** Upper time limit to diagnosis and therapy by ICDs: We use this generic name to prevent disclosure of the 
Manufacturers. The nominal value was “off” in manufacturer A and “on” in the manufacturer B. 
‡ Angiotensin converting enzyme 
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ICD Data Storage and Retrieval: After ICD implantation the patients were followed 
every three months and upon receiving high voltage therapy in our outpatient ICD clinic. The 
devices were interrogated at each session and the complete set of data (including intra-cardiac 
electrograms) was recorded on floppy diskettes. The floppy diskettes were used to retrieve all 
episodes of ICD therapy. All the episodes resulted in ICD therapy, studied independently by 
two electrophysiologists to define the diagnosis. In case of discrepancy in diagnosis the final 
analysis of the arrhythmia episode was made by a consensus of three electrophysiologists  
Definitions: Inappropriate ICD therapy was defined as an anti-tachycardia pacing or 
shock therapy for any rhythm and/or arrhythmia other than ventricular tachycardia or 
fibrillation. Indication of ICD implantation was defined as secondary prevention (n=113) in 
patients who had experienced aborted sudden cardiac death, sustained ventricular arrhythmia, 
or syncope (whose electrophysiologic study [using three basic drive cycle lengths of 600, 500 
and 400 with up to three premature extra-stimuli from right ventricular apex and/or outflow 
tract] showed inducible sustained hemodynamically unstable ventricular arrhythmias). The 
indication of ICD implantation in all the other patients (23 patients with coronary artery 
disease and 26 patients with dilated cardiomyopathy) was categorized as primary 
prevention. 
Statistics: (please also see section one; appropriate ICD therapy) We compared the 
probability of ≥1 inappropriate ICD therapy based on the time to first inappropriate therapy 
between the two groups by the Kaplan-Meier analysis and used log-rank test to generate the 
P-value. A two-tailed p-value < 0.05 was considered statistically significant. 
Results: 
Incidence and reason of inappropriate ICD therapy: Table 1 (see above) shows 
the patients’ baseline characteristics. During the follow up period of 14.3±10 months, 49 
(30%) patients received ≥1 inappropriate ICD therapy. The rate of ≥1 inappropriate ICD 
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therapy in manufacturer A and B ICDs was 26% (n=29) and 41% (n=20), respectively. Higher 
number of women received ICD from manufacturer B and there was a trend toward higher 
prevalence of dilated cardiomyopathy in this group however both failed to reach to statistical 
significance (Table1). Our data showed that the cumulative hazard (Figure1) and reason 
(Table1) of first inappropriate ICD therapy was different between the two manufacturers. The 
probability of ≥1 inappropriate ICD therapy was comparable between the two groups of 
primary and secondary prevention (Figure3, Log-Rank P = 0.279). 
 
 
Figure 1: Kaplan–Meier plot of the cumulative hazard of ≥1 inappropriate ICD therapy 
according to the manufacturer of the ICD 
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As it is shown in table 1 the major difference in the rate of inappropriate ICD therapy 
arise from the “upper time limit to diagnosis and therapy” parameter. While this parameter 
is set off by default in manufacturer A’s ICDs, it is programmed on in the basal default 
settings in the ICDs from the manufacturer B. Excluding the patients with ICDs from 
manufacturer B who received inappropriate ICD therapy due to maximum time to diagnosis 
results in comparable rate of  inappropriate ICD therapy (Figure 2).  
 
Figure 2: Kaplan–Meier plot of the cumulative hazard of ≥1 inappropriate ICD therapy 
according to the manufacturer of the ICD after exclusion of the cases of inappropriate ICD 
therapy due to “upper time limit to diagnosis and therapy” 
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Our data also showed that the cumulative hazard on inappropriate therapy was 
comparable between single and dual chamber ICDs (Figure 3). But why our data and the 
other trials have shown this finding? Ventricular tachycardias can be easily diagnosed in case 
of ventricular rate > atrial rate. This occurs in 80-90% of Ventricular tachycardias which 
occurs in the Ventricular tachycardia zone of dual-chamber ICDs. Hence, additional dual 
chamber discriminators actually apply to only 10-20% of Ventricular tachycardias. 
Improvement in current algorithms in field of tachycardias with 1:1 association and 
management of atrial blanking period in the atrial channel of dual chamber ICDs can 
influence the rate of inappropriate ICD therapy. 
7 
 
Figure 3:  Kaplan–Meier plot of the cumulative hazard of ≥1 inappropriate ICD therapy 
according to the type of the ICD. 
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Discussion 
Although arrhythmia detection enhancements compared to rate-only detection 
decrease the rate of inappropriate ICD therapy without compromising the ICD’s safety the 
rate of inappropriate therapy remains high. 
3-5
 We showed that having all discrimination 
protocols activated with the nominal values, the rate (figure 1) and the reason of (Table 1) 
first inappropriate ICD therapy differs between the two manufacturers. The difference in the 
reasons of the first inappropriate ICD therapy also supports our finding that the different 
devices’ discriminatory algorithm(s) may work differently under default settings. Our data 
showed that the “upper time limit to diagnosis and therapy” parameter was the major reason 
for the difference in the rate of inappropriate ICD therapy. Although excluding this parameter 
could have resulted in the same rate of inappropriate ICD therapy, the reason for these 
therapies remains different between the two manufacturers (Table 1). 
Although to the best of our knowledge there has been no prospective comparison 
between different discrimination protocols, Glikson et al. 
6
 have recently shown that in a dual 
chamber ICD various combinations of arrhythmia discriminators influences the performance 
of ICD with respect to arrhythmia diagnosis and inappropriate ICD therapy. Therefore, as it is 
suggested by our findings it could be assumed that the discriminatory performance of various 
ICDs might be different as they use different protocols and approaches for arrhythmia 
diagnosis and classification. 
7
 However, further studies are needed to better clarify this issue.  
In addition in each ICD the optimum combination(s) of discriminatory parameters 
can influence the performance and specificity of the ICD systems. 
6
 Several investigators have 
shown that optimal dual chamber ICD programming reduces the inappropriate detection of 
supraventricular tachycardia as ventricular tachycardia, 
8-10
 In the future, as the reason of 
inappropriate ICD therapies can be different from patient to patient, in addition to newer more 
accurate discriminatory protocols we would also need ICDs with the ability of customized 
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software installation for different patients and arrhythmic circumstances. This would help to 
reduce the rate of inappropriate ICD therapies. 
8 
In conclusion having all discrimination protocols activated with the nominal values, the rate 
of ≥1 inappropriate ICD therapy (discriminatory performance) differs between the two 
manufacturers. The “upper time limit to diagnosis and therapy” algorithm was the major 
reason in this observed difference in the rate of inappropriate ICD therapy. However, our 
study included a relatively small number of patients. Therefore further larger-scale studies are 
warranted to prospectively compare the performance of various available ICDs’ 
discriminatory protocols, and define the optimum combination of discriminators in each ICD 
to decrease the rate of inappropriate therapy. 
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Effect of Ventricular Tachycardia Cycle Length on Rate of Ventricular 
Arrhythmia Recurrence in Patients with ICD 
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Betreut von Prof. Dr. med. Gerhard Hindricks 
Abstract (Part 3)* 
Some controversies exist regarding the proper treatment of hemodynamically tolerated and 
slow ventricular tachycardia (VT). We intended to assess the effect of cycle length of first VT episode 
on total ventricular arrhythmia burden in a cohort of patients with implanted cardioverter-defibrillator 
(ICD).  
Between March 2000 and March 2005, 195 patients underwent ICD implantation at our 
centre. We included 158 patients (mean age 58.3±12.9 year) with follow up ≥ 3 months in this study. 
Clinical, electrocardiographic, and ICD stored data and electrograms were collected and analyzed. 
During the follow up of 16.7±10.6 months, 45 (28.5%), and 20 (12.6%) patients received first 
appropriate ICD therapy for VT and ventricular fibrillation, respectively. We divided the 45 patients 
with VT (based on the median value of VT cycle length) into two groups. Although patients with VT 
cycle length < 350 had higher total mean number of appropriate ICD therapy (25 versus 6.3, P=0.023), 
during multivariate regression analysis only left ventricular ejection fraction (LVEF) <25% (P=0.020) 
was correlated with total number of appropriate ICD therapy. First VT cycle length (P=0.341), QRS 
duration (P=0.126), age (P=0.405), underlying heart disease (P=0.310), indication of ICD implantation 
(P=0.113), and gender (P=0.886) were failed to predict the total burden of ventricular arrhythmia 
during the follow up period.  
After adjustment for LVEF slower initial VT cycle length per se did not confer a lower risk of 
subsequent ventricular arrhythmia recurrence compared to those with faster VT. LVEF<25% was 
correlated with higher ventricular arrhythmia burden in patients with ICD. 
* published in Journal of Electrocardiology. 2006;39:404-8. Impact Factor (2013): 1.363 
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Introduction: 
Some controversies exist regarding the proper treatment of hemodynamically tolerated 
and slow ventricular tachycardia (VT). AHA/ACC guideline has given ICD a class I 
indication with level of evidence: B in patients with spontaneous sustained VT (irrespective 
of hemodynamic status during arrhythmia) in association with structural heart disease
 1-3
. 
While there is a consensus on treatment of hemodynamically unstable sustained VT, some 




Several studies hitherto have assessed the effect of hemodynamic status of VT on 
mortality. 
5-11
 However, to the best of our knowledge the effect of cycle length of initial 
sustained monomorphic VT (regardless of its hemodynamic status) on the cumulative rate of 
subsequent VT recurrence has not been studied so far. We hereby sough to assess the effect of 
cycle length of first VT episode (as the index arrhythmia) on total number of subsequent 
appropriate ICD therapies as a surrogate for total ventricular arrhythmia burden in a cohort of 
patients with ICD. We hypothesized that the first VT cycle lengths do not influence the total 
sustained ventricular arrhythmia burden. 
Methods: 
Patients Population: Between March 2000 and March 2005, 195 patients (75% male) 
with coronary artery disease (CAD) and dilated cardiomyopathy (DCM) underwent ICD 
implantation at our centre. Among these 158 patients had follow up period ≥ 3 months. 
Among these 45 patients with sustained monomorphic VT as the first arrhythmia requiring 
ICD therapy were included in this study. All the patients gave written informed consent for 
the procedure of ICD implantation. The mean age was 58.3±12.9 years. 
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  ICD Data Retrieval: After ICD implantation the patients were followed at three 
months interval and upon receiving high voltage therapy in our outpatient ICD clinic. The 
devices were interrogated at each session and the complete set of data (including intracardiac 
electrograms) was recorded on floppy diskettes. The floppy diskettes were used in this study 
to retrieve all sustained arrhythmia episodes. Each episode studied by two independent 
electrophysiologists to define the diagnosis. In case of discrepancy in diagnosis the final 
analysis of the arrhythmia episode was made by a consensus of three electrophysiologists. 
Beside from diagnosis, the time of arrhythmia after implantation and the mode of therapy 
were recorded. 
Implanted ICDs and programming: The implanted devices were manufactured by 
Medtronic (n=115, [GEM-VR, GEM-DR, GEM-II-VR, GEM-II-DR, GEM-III-VR, GEM-III-
DR, Marquis-VR, Marquis-DR] Medtronic Inc., Minneapolis, MN, USA) and St. Jude (n=43, 
[Photon-VR, Photon-DR, Photon-µ-VR, Photon-µ-DR, Atlas-VR, Atlas-DR, Epic-VR, and 
Epic-DR] St. Jude Medical Inc. Sylmar, CA, USA). In all the devices we defined ventricular 
fibrillation zone (300 ms) plus one VT zone (400 ms). If the patient had an episode of 
spontaneous or induced sustained monomorphic VT slower than 370 ms we extended the VT 
zone to VT cycle length+40 msec.  
Definitions: Appropriate ICD therapy was defined as an anti-tachycardia pacing or 
shock therapy for ventricular tachycardia or fibrillation. First therapy in the VT zone was 
programmed as three sequences of anti-tachycardia pacing. The initial episode consisted of 8 
beats with cycle length of 88% of VT cycle length, and shortest interval of 200 msec. If the 
initial episode failed to terminate VT, the subsequent episode’s cycle length was reduced by 
20 msec. Second to sixth therapies were programmed as Cardioversion. Diagnosis of 
monomorphic VT was defined as a regular tachycardia with monomorphic intra-cardiac 
ventricular electrogram in the VT detection zone with the change in the morphology of the 
Predictors of ICD Therapies  Arash Arya 
- 34 - 
 




Statistics: Variables are expressed as mean ± SD, and percentage. Differences in 
frequency of characteristics were assessed by independent sample student’s t-test between 
two groups and analysis of variance for comparison between three groups for continuous 
variables. Chi-square statistics (or fisher’s exact test if applicable) used for discrete variables. 
A two-tailed p-value < 0.05 was considered statistically significant. We used SPSS® 13.0 
(SPSS Inc. Chicago, USA) for data storage and analysis. 
Results: 
Baseline Characteristics: One hundred fifty eight patients with ICD were followed 
for a mean of 16.7±10.6 months. The mean follow up time after first ICD therapy for 
monomorphic ventricular tachycardia was 11.2 ± 8.9 months. Table 1 shows the basic 
characteristics of the patients based on the status of appropriate ICD therapy during the follow 
up period. We selected the 45 patients with sustained monomorphic VT as the first ventricular 
arrhythmia requiring therapy after ICD implantation to assess the effect of its cycle length on 
total number of appropriate ICD therapy as a surrogate for total ventricular arrhythmia 
burden.  
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Number 45 20 93 -- 
Age (year) 58±14 57.6±12.5 58±13.5 0.886 













Underlying heart disease:      






































Mean number of appropriate ICD therapy 16±28 7±9 -- 0.0001 













Β-blocker therapy 22 (49%)  14 (70%) 56 (60%) 0.234 
Angiotensin converting enzyme Inhibitors 42 (93%) 17 (85%) 80 (86%) 0.422 
Digoxin 18 (40%) 10 (50%) 41 (44%) 0.749 
Amiodarone 32 (71%) 11 (55%) 57 (62%) 0.407 
 
* The subgroups of left ventricular ejection fraction and QRS duration are chosen based on the median values in the study population.  ** 
Left ventricular ejection fraction was significantly correlated with total number of appropriate ICD therapy during the follow up period 
(P=0.005). ‡ Patients with sustained monomorphic ventricular tachycardia requiring ICD therapy. These comprise our study population. † 
Patients with ventricular fibrillation requiring ICD therapy. ¶ Ventricular arrhythmia.  
 
Number of appropriate ICD therapy based on initial VT cycle length: Table 2 
depicts the baseline characteristics of patients with sustained monomorphic ventricular 
tachycardia as the index arrhythmia according to its cycle length. Patients with initial VT 
cycle length < 350 ms were younger, had higher prevalence of DCM as the underlying heart 
disease, had lower left ventricular EF, and had higher mean number appropriate ICD therapy.  
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Table 2: Baseline characteristics of patients with sustained monomorphic ventricular tachycardia as 
the reason for first appropriate therapy * 
Variables ACL**<350ms ACL≥350 ms P-Value 
Number 23 22 -- 
Age (year) 53±17 63±9 0.026 










Underlying heart disease:      







































Β-blocker therapy 12 (52%) 10 (45%) 0.652 
Angiotensin converting enzyme Inhibitors 21 (91%) 21 (95%) 0.537 
Digoxin 12 (52%) 6 (27%) 0.088† 
Amiodarone 16 (70%) 16 (72%) 0.815 
Mean¶ number of appropriate ICD therapy 25±7.7 6.3±1.3 0.023§ 
First arrhythmia cycle length (ms) 310±23 
(270 – 345) 
380±16 
(350 – 420) 
0.0001 






















* The subgroups of arrhythmia cycle length, left ventricular ejection fraction, and QRS duration are chosen based on the median values in 
the study population.  
** Arrhythmia cycle length. † Mantel-Haenszel P value for re-analysis stratified for ejection fraction = 0.095. 
¶ Expressed as mean ± standard error of mean. § During multiple regression analysis presenting VT cycle length failed to correlate with 
total number of appropriate ICD therapy as a surrogate for total arrhythmia burden (P=0.341). The medications are based on the medical 
history at the time of first appropriate ICD therapy. 
 
We hypothesized that other confounding variable(s) might have resulted in the 
observed difference of mean number of appropriate ICD therapy between subgroups of VT 
cycle length. We used multiple regression analysis to find the predictors of total number of 
appropriate ICD therapy among patients with sustained monomorphic VT. Left ventricular EF 
< 25% was the only variable correlated with the total number of appropriate ICD therapy in 
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these patients (P=0.020). In addition, presenting VT cycle length (P=0.341), QRS duration 
(P=0.126), age (P=0.405), underlying heart disease (P=0.310), indication of ICD implantation 
(P=0.113), and gender (P=0.886) were failed to predict the total number of appropriate ICD 
therapy during the follow up period.  
First and subsequent ventricular arrhythmia cycle lengths: Table 2 (see above) 
shows first VT cycle length in each group. Although the mean longest arrhythmia cycle 
length during follow up was different among the two groups (P = 0.001), the shortest 
tachycardia cycle length was comparable between the two groups (P = 0.235). In addition 
during follow up 22% (n=5) and 19% (n=4) of the ICD recipients with initial fast and slow 
VT experiences at least one episode of potentially life threatening 
10 
fast VT, defined as VT 
with cycle length ≤ 250 ms, respectively (P = 0.853). 
Discussion: 
We showed that (1) Among our ICD patients who had sustained monomorphic VT as 
the first arrhythmia after ICD implantation the LVEF < 25% correlated with the total number 
of appropriate ICD therapy as a surrogate for total ventricular arrhythmia burden; (2) After 
adjustment for left ventricular EF, initial VT cycle length did not correlate with the total 
number of appropriate ICD therapy during multivariate regression analysis (P=0.341); (3) The 
frequency of potentially life threatening fast VT 
10
 and the mean shortest VT cycle length 
after first VT were comparable between the two groups. 
To the best of our knowledge this is the first study assessing the effect of VT cycle 
length on subsequent VT recurrence. The initial VT cycle length did not correlate with VT 
recurrence during the follow up. In addition the mean shortest VT cycle length and the 
occurrence of potentially lethal fast VT were comparable between the two groups. There 
might be an association between VT cycle length and symptoms. Therefore, one could 
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suggest that the slower VT might have been associated with more benign symptoms 
compared to faster VTs. 
10
 
Several studies have evaluated the effect of hemodynamic status and concomitant 
symptoms on long term outcome of patients with sustained monomorphic VT. Sarter et al. 
have suggested a better prognosis for hemodynamically tolerated VT 
8
 (however, some 
debates exist on their data 
4, 9
) but other showed that the risk is similar to patients with more 
severely symptomatic VT. Raitt et al. in a subgroup analysis of AVID registry 
6
 showed that 
the absence of symptoms with sustained VT does not predict a benign prognosis. Olson et al. 
assessed the predictors of sudden cardiac death in 122 patient 
9
 and showed that the rate of 




Bocker et al. studied the natural course of 50 patients (82%, CAD) with 
hemodynamically tolerated VT who received ICD. 
10
 They showed that during mean follow 
up of 17 months, 33 patients (66%)
 
had 3861 episodes of ventricular tachycardia which is 
comparable to other studies 
5, 11
. Eleven patients (22%) had
 
episodes of potentially life-
threatening fast VT (CL<250 ms) during follow up period. Had the ICD not been implanted in 




We found that EF < 25% define a subgroup of patients with ICD who are at higher 
risk of subsequent ICD therapy after initial VT. Freedberg et al. followed 125 patients with 
ICD for 408±321 days and found that first appropriate ICD therapy which occurred in 46% of 
patients, tends to occur in patients presenting with sustained monomorphic VT and left 
ventricular EF <25%. 
5
 
Predictors of ICD Therapies  Arash Arya 
- 39 - 
 
Finally, Sadoul et al. have recently showed that slow VT (defined as VT < 148 beat 
per minute) occurs in 30% of ICD recipients without prior history of symptomatic or ECG 
documented slow VT exhibited slow VT during a 1-year follow-up. 
13
 However, they did not 
assess the effect of slow VT on the rate of recurrence, cycle length, and hemodynamic status 
of subsequent sustained arrhythmic episodes. 
13
 
In conclusion: After adjustment for left ventricular EF, initial VT cycle length did not 
predict subsequent VT recurrence in our patients with ICD. In addition mean shortest VT 
cycle length and prevalence of potentially lethal fast VT was comparable between the two 
groups. Using multiple regression analysis, only left ventricular EF < 25% defined a subgroup 
of patients who are higher risk appropriate ICD therapy due to VT recurrence after initial ICD 
therapy. This may (at least partially) explain the discrepancy between various studies 
conducted on effect of slow VT on prognosis. Further prospective studies are warranted to 
clarify this issue. 
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Abstract (Teil 4)* 
Cardiac resynchronization therapy (CRT) reduces the mortality in selected patients with heart 
failure. However this may not be entirely related to its beneficial hemodynamic effects. We assessed 
retrospectively the effect of CRT on incidence of appropriate therapy in patients with implantable 
cardioverter-defibrillator (ICD).  
Sixty five patients (mean age 58±13 years, 48 male) with ICD (31 with biventricular ICD and 
34 with dual chamber ICD) were included in the study. Clinical, electrocardiographic, and ICD stored 
data and electrograms were collected. Biventricular and dual chamber ICDs were implanted in 31 and 
34 patients respectively, who had either ischemic (n=36) or dilated cardiomyopathy (n=29). Thirty two 
(49%) patients received ≥ 1 appropriate ICD therapy during follow up period of 11±8 months. Thirty-
five percent and 62% of patients with biventricular (n=11) and dual chamber ICDs (n=21), 
respectively, received appropriate ICD therapy during follow up period (odds ratio = 0.340, P=0.048). 
Stratifying the patients according to underlying heart disease and ejection fraction resulted in adjusted 
odds ratio = 0.239, P=0.029). We compared the rate of ≥ 1 appropriate ICD therapy between the two 
groups by Kaplan-Meier analysis and the Log-Rank test which resulted in P = 0.027.  
In this retrospective analysis, biventricular pacing was associated with a decrease in the 
incidence of sustained ventricular arrhythmias requiring ICD therapy. The antiarrhythmic effect of 
biventricular pacing could contribute to reduction of mortality shown in recent large scale clinical 
trials on CRT. However, further prospective studies are warranted to clarify this issue. 
* published in Heart Rhythm. 2005;2:1094-8.. Impact Factor (2013): 5.045 
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Introduction: 
Cardiac resynchronization therapy is an established mode of therapy in selected 
symptomatic patients with heart failure due to systolic dysfunction. 
1
 Recently published large 
scale clinical trials of CRT confirmed the favorable effects of CRT on symptoms, the quality 
of life, ventricular function, and blood pressure and showed that CRT significantly reduces 
the risk of mortality. 
2, 3
 Calculations based on data from Cardiac Resynchronization — Heart 
Failure trial depicted that, for every nine biventricular pacemaker implanted, one death and 
three hospitalizations for major cardiovascular events were prevented. 
2
 The reduction in 
mortality by CRT is at least in some part is related to homodynamic improvement. 
1
  
Some experimental studies have suggested that epicardial pacing of left ventricle in 
CRT prolongs QT interval and increases the transmural dispersion of refractoriness. 
4
 In 
addition some cases of increase in ventricular arrhythmias following CRT have been reported 
in the literature.
5-6
 Contrary to these, several clinical studies have suggested the opposite and 
showed that the CRT could also reduce the mortality by decreasing the incidence of lethal 
ventricular arrhythmias. 
7-14 
We hereby conducted a retrospective case-control study to assess 
the effect of CRT on incidence of appropriate therapy, as a surrogate for sustained ventricular 
arrhythmias (see definitions), in patients with implantable cardioverter-defibrillator (ICD). 
Methods: 
Patients Population: Between December 2002 and February 2005, 31 patients 
underwent transvenous biventricular ICD implantation at our centre. In two patients the left 
ventricular lead was implanted via thoracotomy. All these patients had QRS width ≥ 120 ms 
and standard indication for CRT 
1
 and ICD implantation (see definitions). During the same 
period 68 patients with coronary artery disease (CAD) or dilated cardiomyopathy (DCM) 
received dual chamber ICD at our centre. To provide an adequate comparable control group, 
among these 68 patients we selected all the patients with QRS duration ≥ 120 ms (n=34) as 
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the control group. The bradycardia pacing of dual chamber ICDs were programmed to VVI 
with the rate of 40 beats per minute to prevent unnecessary ventricular pacing, except in 
patients with an established indications for cardiac pacing (n=5). 
15
 All the patients gave 
written informed consent for the procedure of ICD implantation. The mean age was 58±13 
years. Table 1 shows the basic characteristics of the patients. 
Table 1: Baseline characteristics of patients 
Variables ICD-DR† CRT-D¶ P-Value 
Number 34 31 -- 
Follow up period 11±8 10.3±6 0.455 
Age (year) 57±13 58±12 0.849 
Sex:  
                        Male 









Underlying heart disease: 
                        Coronary artery disease 









LVEF * (%) 26±8 22±6 0.013 
QRS duration (ms) 146±30 149±25 0.711 
Corrected QT interval (ms) 480±58 473±68 0.631 











Beta-blocker therapy (%) 53% 40% 0.250 
ACE ** Inhibitors 88% 83% 0.371 
Amiodarone 62% 53% 0.409 
 
 
* Left ventricular ejection fraction. 
** Angiotensin converting enzyme. 
† Dual chamber implantable cardioverter-defibrillator. 
¶ Implantable cardioverter-defibrillator with biventricular pacing option. 
  
ICD Data Storage and Retrieval: After ICD implantation the patients were followed 
on a regular basis (3 months) and upon receiving high voltage therapy in our outpatient ICD 
clinic. The devices were interrogated at each session and the complete set of data (including 
intracardiac electrograms) was recorded on floppy diskettes. The summary of the episodes 
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were also recorded in the patient’s file. The floppy diskettes were used in this study to retrieve 
all sustained arrhythmia episodes. Each episode studied by two independent 
electrophysiologists (AA and MRD) to define the diagnosis. In case of discrepancy in 
diagnosis the final analysis of the arrhythmia episode was made by a consensus of three 
electrophysiologists (AA, MRD, and MH). Beside from diagnosis, the time of arrhythmia 
after implantation and the mode of therapy were recorded.  
Definitions: Appropriate ICD therapy was defined as an antitachycardia pacing or 
shock therapy for ventricular tachycardia or fibrillation. All the patients who received 
biventricular ICD had standard indications for ICD implantation. 
16
 Indication of ICD 
implantation was defined as secondary prevention (n=44) in patients who had experienced 
aborted sudden cardiac death, sustained ventricular arrhythmia, or syncope (n=9, with 
structural heart disease whose electrophysiologic study showed inducible sustained 
hemodynamically unstable ventricular arrhythmias). The indication of ICD implantation in all 
the other patients (n=21 with MADIT, MUSTT like indications in those with CAD [n=10] 
and asymptomatic patients with DCM [n=11] with nonsustained VT during Holter monitoring 
who had inducible sustained hemodynamically unstable ventricular arrhythmia during 
electrophysiologic study) was categorized as primary prevention. 
16 
  
Statistics: Variables are expressed as mean ± SD, and percentage. Differences in 
frequency of characteristics were assessed by independent sample student’s t-test for 
continuous variables. Chi-square statistics (or fisher’s exact test if applicable) used for 
discrete variables. Probability of ≥ 1 appropriate ICD therapy based on the time to first 
appropriate ICD therapy between the two groups determined by the Kaplan-Meier analysis 
with Mantel-Cox (Log-Rank) test. The time to first appropriate ICD therapy plotted according 
to the Kaplan-Meier method. We used Mantel-Haenszel test to generate P value for the 
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reported odds ratios. A two-tailed p-value < 0.05 was considered statistically significant. We 
used SPSS® 13.0 (SPSS Inc. Chicago, USA) for data storage and analysis. 
Results: 
Baseline Characteristics: Sixty five patients with biventricular and dual chamber 
ICD were followed for a mean of 11±8 months. Biventricular and dual chamber ICDs were 
implanted in 31 and 34 patients, respectively. We compared patients’ characteristics between 
two types of ICD (Table 1, see above). Patients with biventricular ICD had lower left 
ventricular EF (22±6 versus 26±8, P=0.013); and higher prevalence of DCM as underlying 
heart disease (61% versus 30%, P=0.013). Other variables were comparable between two 
groups. 
Appropriate ICD therapy: Thirty two (49%) patients received ≥ 1 appropriate ICD 
therapy during the follow up period. Ventricular tachycardia and fibrillation (based on 
detection zones) were responsible for first appropriate ICD therapy in 20 (62.5%) and 12 
(27.5%) patients, respectively. The proportion and cycle length of these ventricular 
arrhythmias were comparable between the two groups (all P = NS).    
Thirty five percent and 62% of patients with biventricular (n=11) and dual chamber 
ICD (n=21), respectively, received appropriate ICD therapy during the follow up period 
(Odds ratio = 0.340, 95% confidence interval = 0.125 – 0.935, P=0.048). The mean number of 
appropriate ICD therapies in patients with dual chamber and biventricular ICDs were 13±32 
(range: 0-132) and 1.3±2.5 (range: 0-9), respectively (P=0.047).  
Interaction between type of ICD and probability of ≥ 1 appropriate ICD therapy: 
Figure 1 shows the comparison of the differences in ≥ 1 appropriate ICD therapy using 
Kaplan-Meier survival curves for the two device groups, with application of Mantel-Cox 
(Log-Rank) test (P = 0.027). Among 34 and 31 patients with dual chamber and biventricular 
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ICDs, 62% and 35% received appropriate ICD therapy, respectively (Odds ratio = 0.340, 95% 
confidence interval = 0.125 – 0.935,  P=0.048). We repeated the analysis by stratifying the 
patients according to underlying heart disease and left ventricular EF. The subgroups of left 
ventricular EF was divided based on the median value (25%) in the study population. The 
adjusted odds ratio was 0.239 (95% confidence interval = 0.1 to 0.84, P=0.029). 
 
Figure 1: Kaplan–Meier plot of the Time to the first inappropriate therapy according to types 
of ICD. We used Log-Rank (Mantel-Cox) test to generate the P-value.  
ICD-DR: Dual chamber ICD. CRT-D: Biventricular ICD. 
 
Prevalence and number of nonsustained VTs: Forty eight (74%) patients had 
nonsustained VT during the follow up period. Although there was a trend toward higher 
prevalence of NSVT in patients with dual chamber ICDs compared to those with biventricular 
ICDs (80% versus 68%), it failed to reach to statistical significance (P = 0.258). Although 
there was also a trend toward the higher mean number of nonsustained VTs in patients with 
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dual chamber ICDs (155±394 [range: 1 – 1642] versus 33±95 [range: 1 – 436]), it failed to 
reach to statistical significance (P = 0.113).  
Discussion: 
Main finding: Biventricular pacing decreased the rate of appropriate ICD therapy 
(including both antitachycardia pacing and shock) by suppressing the occurrence of sustained 
ventricular arrhythmias requiring ICD therapy. During follow up period patients with 
biventricular ICD received 66% less appropriate ICD therapy compared to those with dual 
chamber ICD (figure 1 and 2). 
 
Figure 2: Effect of biventricular pacing on the incidence of appropriate ICD therapy. Unadjusted odds ratios and 
95% confidence intervals are shown. The subgroups of age, ejection fraction, and QRS width are divided based 
on the median values of the study population. ICD-DR: Dual chamber ICD. CRT-D: Biventricular ICD. 
 
The recent clinical trials on CRT confirmed that it significantly reduces the risk of 
death. 
2, 3
 However the reduction in mortality by CRT may not be related entirely to its 
favourable homodynamic effects. Several potential mechanisms may explain the observed 
antiarrhythmic effect of CRT.  
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Although we did not assess the hemodynamic response to the CRT in our study, 
improvement in left ventricular performance could partly explain the decreased incidence of 
appropriate ICD therapy in patients with biventricular ICDs.
14, 18
 The hemodynamic 
improvement following CRT could decrease the stretch on myocardium and modulate the 
autonomic nervous system activity and these in turn would reduce the incidence of lethal 
ventricular arrhythmias. 
14, 18
 Several studies have shown that biventricular pacing decreases 
the frequency of ventricular ectopy. 
7, 10
 Reducing the ventricular ectopy which can trigger 
sustained ventricular arrhythmias could decrease the incidence of sustained ventricular 
arrhythmias and appropriate ICD therapy.  
Several studies have shown that biventricular pacing reduces the inducibility of 
ventricular tachycardia. 
9-11
 Kowal et al. in a prospective randomized study evaluated the 
acute electrophysiologic effects of biventricular pacing. 
9
 They showed that biventricular 
compared to right ventricular programmed electrical stimulation significantly reduces the 
induction of ventricular tachycardia (but not ventricular fibrillation) and hypothesized that the 
mechanism of arrhythmia suppression by biventricular pacing is due to preexcitation of the 
area of slow conduction responsible for re-entrant arrhythmias and significant increase in the 
local left ventricular coupling interval. 
9
 
Experimental studies have suggested that epicardial left ventricular pacing increases 
the transmural dispersion of refractoriness and hence biventricular pacing may potentially 
cause proarrhythmia in selected patients with CRT. 
4, 14
 Berger et al. have recently assessed 
the effect of biventricular pacing on ECG markers of ventricular repolarization in patients 
with congestive heart failure and showed that using a high resolution surface ECG, 
biventricular pacing actually significantly reduced ECG markers of ventricular dispersion of 
repolarization which could further contribute to the antiarrhythmic effects of CRT. 
13
 
Higgins et al. in a similar study to ours showed that in patients with standard 
indications for ICD, appropriate ICD therapy was less common with biventricular ICDs. 
7
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However, several points merit consideration. In their study all the left ventricular leads were 
placed via thoracotomy while left ventricular leads where positioned via coronary sinus in all 
but two of our patients. In Higgins’ study only 32 of 54 (59%) patients were suitable for the 
final paired analysis; and duration of observation in each mode of pacing was only three 
months. 
17 
Our study with a larger patient population confirmed the beneficial effect of 
biventricular pacing on reduction of appropriate ICD therapy in a longer follow up duration. 
However, ICD therapy should not be equated with reduction in sudden cardiac death, 
therefore larger prospective studies with cardiac and all cause mortality as the endpoints are 
warranted to clarify this issue. 
While the bulk of evidences are in favour of antiarrhythmic effects of CRT, 
7-14
 
several case reports have shown the increased occurrence of ventricular arrhythmia following 
biventricular pacing or ICD implantation. 
5, 6
 In addition, in Cardiac Resynchronization — 
Heart Failure study, despite statistically significant lower absolute number of deaths classified 
as sudden in CRT group compared to control group, the proportion of deaths which were 
classified as sudden cardiac death were comparable between the two groups. The mode of 
death was classified as sudden in 38 of the 120 patients who died in the medical therapy 
group (32 percent) and in 29 of the 82 patients who died in the CRT group (35 percent). 
2
 
Although the underlying mechanism(s) in the above mentioned case reports were not 
exactly clear, physicians should be aware of occasional proarrhythmic effects of CRT. The 
biventricular pacing induced ventricular tachycardia is one of the study endpoints of 
PACMAN trial – pacing for cardiomyopathies, a prospective single blinded study ongoing in 
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Conclusion: in selected patients with heart failure who had accepted indications for ICD 
implantation biventricular pacing reduced the incidence of appropriate ICD therapy, as a 
surrogate for sustained ventricular arrhythmias. Further large scale prospective studies are 
warranted to assess the potential antiarrhythmic effects of CRT. 
 
Implication: The antiarrhythmic effect of biventricular pacing could contribute to reduction 
of mortality seen in CRT patients. 
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----------------------------------------------------------------------------------------------------------------- 
There is no controversy that ICD in selected patients reduces the long term mortality. 
However, appropriate and/or inappropriate shocks in patients with ICD are associated with 
increased mortality and morbidity. Identifying the predictors of ICD therapies could help to 
identify those at risk and reduce the incidence of these therapies through appropriate measures 
and therapies which may improve mortality and morbidity in patients with ICD. I hereby 
summarize my four published studies on predictors of appropriate and inappropriate ICD 
therapies. 
In the first study we assess the prevalence and predictors of electrical storm in 162 
patients with ICD who were followed for a mean of 14.3±10 months. Electrical storm was 
defined as ≥ 3 episodes of ventricular tachycardia and/or fibrillation requiring ICD therapy in 
a one day period. During our follow up period the patients received mean number of 17±29 
(range 1 – 132) appropriate ICD therapy. Among these the number of appropriate ATP was 
11.9±28 (range 0 – 131) and the number of appropriate shock therapy was 5.1±9.9 (range 1 – 
56). The success rate of ATP therapy among the episodes in the VT detection zone was 88%. 
Predictors of electrical storm were found by Cox regression. In the Cox-regression model 
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ejection fraction < 25% (P=0.007), QRS width ≥ 120 ms (P=0.002), and lack of adjunctive 
beta-blocker and angiotensin-converting enzyme inhibitors (both P < 0.001) were correlated 
with the higher probability of electrical storm during the follow up period.  
Therefore this study showed that optimum medical therapy with beta-blockers and 
angiotensin-converting enzyme inhibitors could reduce the incidence of this devastating 
complication in patients with ICD. In addition low left ventricular ejection fraction (< 25%) 
and wide QRS complex (≥ 120 ms) identify patients who are at higher risk of appropriate ICD 
therapies and therefore may profit more from prophylactic catheter ablation of ventricular 
arrhythmias. 
The algorithms that should discriminate VT or VF from less lethal supra-ventricular 
arrhythmias do not always work perfectly. As many as one-third of the patients who have an 
ICD implanted, receive inappropriate ICD shocks. Inappropriate shocks occur when the 
device delivers a shock for a reason other than a ventricular arrhythmia. Inappropriate ICD 
shocks are also associated with increased mortality. Given the traumatic nature of ICD 
shocks, it would be ideal if the ICD could always successfully distinguish ventricular 
arrhythmias from non–life-threatening tachyarrhythmias and administer only appropriate 
shocks for VT or VT. Several factors influence the incidence and prevalence of inappropriate 
ICD shocks. Every ICD manufacturer uses a different discrimination protocol and therefore 
the rate of inappropriate ICD therapies might be different among various ICD models.  
However, at the time of our second study to the best of our knowledge no study assessed the 
rate of inappropriate ICD shocks between different ICD manufacturers.  
In the second study immediately after ICD implantation in 162 patients all the 
detection and discrimination criteria were activated with the nominal values. We used the 
nominal values after implantation for comparison of discriminatory protocols of the two 
manufacturers under default settings. After first inappropriate ICD therapy if deemed 
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necessary, the attending physicians were able to modify ICD programming and optimize 
medical treatment in order to decrease the rate of inappropriate ICD therapy. During the 
follow up period of 14.3±10 months, 49 (30%) patients received ≥1 inappropriate ICD 
therapy. The rate of ≥1 inappropriate ICD therapy in manufacturer A and B ICDs was 26% 
(n=29) and 41% (n=20), respectively (P<0.05). The rate of inappropriate ICD therapies was 
comparable between patients with single and two chamber ICDs (P=0.85).  
Therefore, having all discrimination protocols activated with the nominal values, the 
rate of ≥1 inappropriate ICD therapy (discriminatory performance) differs between the two 
manufacturers. The “upper time limit to diagnosis and therapy” algorithm was the major 
reason in this observed difference in the rate of inappropriate ICD therapy. Therefore, optimal 
ICD programming based on ICD model and manufacturer may help reducing the rate of 
inappropriate ICD therapies. 
Some controversies exist regarding the proper treatment of hemodynamically tolerated 
and slow ventricular tachycardia (VT). In the third part of the manuscript we sough to assess 
the effect of cycle length of first VT episode (as the index arrhythmia) on total number of 
subsequent appropriate ICD therapies as a surrogate for total ventricular arrhythmia burden in 
a cohort of patients with ICD. We hypothesized that the first VT cycle lengths do not 
influence the total sustained ventricular arrhythmia burden.   
One hundred fifty eight patients with ICD were followed for a mean of 16.7±10.6 
months. We showed that: (1) after adjustment for left ventricular ejection fraction, initial VT 
cycle length did not correlate with the total number of appropriate ICD therapy (P=0.341) (2) 
the frequency of potentially life threatening fast VT (i.e. cycle length ≤ 250 ms) and the mean 
shortest VT cycle length after first VT were comparable between the two groups with initial 
fast and slow VTs, respectively. Therefore, patients with slower VTs were at the same risk 
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compared to those with faster VTs, with respect to total ventricular arrhythmia burden and the 
frequency of subsequent fast VTs.  
In the forth manuscript we conducted a retrospective case-control study to assess the 
effect of cardiac resynchronization therapy (CRT) on incidence of appropriate therapies, as a 
surrogate for sustained ventricular arrhythmias, in patients with ICD. Sixty five patients with 
biventricular (n=31) and dual chamber ICD (n=34) were followed for a mean of 11±8 months. 
Thirty two (49%) patients received ≥ 1 appropriate ICD therapy during the follow up period. 
Ventricular tachycardia and fibrillation (based on detection zones) were responsible for first 
appropriate ICD therapy in 20 (62.5%) and 12 (27.5%) patients, respectively. Thirty five 
percent and 62% of patients with biventricular (n=11) and dual chamber ICD (n=21), 
respectively, received appropriate ICD therapy during the follow up period (Odds ratio = 
0.340, 95% confidence interval = 0.125 – 0.935, P=0.048). The mean number of appropriate 
ICD therapies in patients with dual chamber and biventricular ICDs were 13±32 (range: 0-
132) and 1.3±2.5 (range: 0-9), respectively (P=0.047).  
In conclusion in our case-control study in selected patients with heart failure who had 
accepted indications for ICD implantation, CRT reduced the incidence of appropriate ICD 
therapy, as a surrogate for sustained ventricular arrhythmias. 
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